ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1192

Electrolyte Disturbances Among Those with Malignancy on Anti-Neoplastic Agents

Session Information

Category: Fluid, Electrolyte, and Acid-Base Disorders

  • 902 Fluid, Electrolyte, and Acid-Base Disorders: Clinical

Authors

  • Murashima, Miho, Nagoya Shiritsu Daigaku, Nagoya, Aichi, Japan
  • Ide, Atsuki, Nagoya Shiritsu Daigaku, Nagoya, Aichi, Japan
  • Ono, Minamo, Nagoya Shiritsu Daigaku, Nagoya, Aichi, Japan
  • Mizuno, Masashi, Nagoya Shiritsu Daigaku, Nagoya, Aichi, Japan
  • Suzuki, Taisei, Nagoya Shiritsu Daigaku, Nagoya, Aichi, Japan
  • Hamano, Takayuki, Nagoya Shiritsu Daigaku, Nagoya, Aichi, Japan
Background

The clinical characteristics of electrolyte disturbances among patients with malignancy in contemporary cohorts are lacking.

Methods

This is a retrospective cohort study on 2644 patients with malignancy on anti-neoplastic agents from 2019 to 2020. Antineoplastic agents associated with electrolyte disturbances were examined by multi-level mixed-effects logistic regression analyses. The data were adjusted for age, sex, serum albumin, eGFR, kinds of malignancy, and other medications which potentially affect electrolytes.

Results

Mean age was 64.8 (15.8) years, 55.5% were male, and median eGFR was 72.9 (58.1-88.1) mL/min/1.73m2. The prevalences of hyponatremia (Na ≤130 mEq/L), hypomagnesemia (Mg ≤1.5 mg/dL), hypophosphatemia (P ≤2.0 mg/dL), and hypokalemia (K≤3.0 mEq/L) were 2.1 (1.8-2.2), 2.0 (1.7-2.3), 1.7 (1.6-1.9), and 1.2 (1.1-1.4) events/100 patient-measurements, respectively. The use of bortezomib was associated with hyponatremia (OR: 3.04 [1.96-4.71]) and three immnue checkpoint inhibitors were significantly associated with hyponatremia. The use of cetuximab and gemccitabine were strongly associated with hypomagnesemia (OR 11.79 [7.56-18.38] and 5.95 [3.36-10.55], respectively). Other agents associated with electrolyte disturbances were shown in Table. Other than anti-neoplastic agents, lower albumin levels were consistently associated with development of electrolyte disturbances.

Conclusion

Electrolyte disturbances were common and associated with the use of novel anti-neoplastic agents among those with malignancy. Identifying the agents and patient population at high risk of developing electrolyte disturbances is important in taking appropriate preventive measures and monitoring for those undergoing treatments with anti-neoplastic agents.